Prostate Cancer
Conditions
Interventions
treatment group:Neoadjuvant Docetaxel+Goserelin+Radical Prostatectomy
control group:Radical Prostatectomy
Sponsors
Department of Urology, Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) pathology confirmed prostate adenocarcinoma; 2) very high risk locally advanced prostate cancer: TNM more than at least T3b; 3) no distant metastasis and lymphnode metastasis confirmed by imaging diagnosis; 4) To be aged 18-75 years old; 5) life expectancy longer than at least 10 years; 6) ECOG 0-1; 7) absolute white blood cell count more than at least 4.0*10^9/L, platelet count more than at least 100*10^9/L, Hemoglobin more than at least 90g/L, adequate hepatic and renal function; 8) has not been treated with hormone therapy or any kind of Cytotoxic drugs before; 9) all patients provided written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1) have contraindications or suspected to be allergic to the involved drugs; 2) undergoing other anti-tumor treatments simultaneously; 3) those who has had other malignant disease, except for properly treated basal cell or squamous cell skin cancer, ervical carcinoma in situ, or patients with other cancers who had at least 5 years disease free survival; 4) immunodeficiency, AIDS; 5) severe disfunction of the heart, lung, liver and kidney; 6) severe infections or active infections; 7) known or suspected noncompliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year biochemical recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| positive rate of margin;post operation PSA; | — |
Countries
China
Contacts
Public ContactYe Dingwei
Outcome results
None listed